ArticleCell reports2023
Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 18 citations in OpenAlex.
- Functional validation of driver mutation-specific uveal melanoma biomarkers: role of COL9A3 in cancer cell plasticity.The Journal of pathology · 2026Article
- Oncogenic Gαq Signaling Remodels the Tumor Surfaceome and Rewires Intracellular Networks in Uveal Melanoma Models.Cancers · 2026Article
- Metastasis-related genomic aberrations and evolutionary trajectory in uveal melanoma.Experimental & molecular medicine · 2026Article
- Article
- Review
- Ephrin Receptors and Ephrin Ligands in Uveal Melanoma: A Big Data Analysis Using Web Resources.International journal of molecular sciences · 2025Article
- Identification of targetable epigenetic vulnerabilities for uveal melanoma.Cell death & disease · 2025Article
- Mitfa-Independent Melanocyte Progenitors are Highly Susceptible to GNAQ-induced Uveal Melanoma in Adult Zebrafish.bioRxiv : the preprint server for biology · 2025Article
- Co-isolation of human donor eye cells and development of oncogene-mutated melanocytes to study uveal melanoma.BMC biology · 2025Article
- DNA Damage, Telomere and Centromere Dysfunction in Chromothripsis Rearrangements.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Mechanism of hepatotoxicity induced by ethanol extract ofFrontiers in pharmacology · 2025Article
- Azacytidine treatment affects the methylation pattern of genomic and cell-free DNA in uveal melanoma cell lines.BMC cancer · 2024Article
- Protein and mRNA Expression in Uveal Melanoma Cell Lines Are Related to GNA and BAP1 Mutation Status.Investigative ophthalmology & visual science · 2024Article
- Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.Molecular biomedicine · 2024Review
- A prognostic nomogram for the cancer-specific survival rate of choroidal melanoma using the Surveillance, Epidemiology, and End Results database.Frontiers in medicine · 2024Article
- Major response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature.Frontiers in oncology · 2024Article
- Novel uveal Melanocyte cell lines display distinct features from uveal melanoma.Advances in ophthalmology practice and researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 10 institutions in 4 countries.
David GentienTranslational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France. Electronic address: dgentien@curie.fr.
Elnaz Saberi-AnsariTranslational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; INSERM U830, Research Center, Institut Curie, PSL Research University, 75005 Paris, France.
Nicolas ServantINSERM U900, Mines ParisTech, 75248 Paris, France.
Ariane JollyGenoSplice, Paris, France.
Pierre de la GrangeGenoSplice, Paris, France.
Fariba NématiTranslational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75248 Paris, France.
Géraldine LiotInstitut Curie, PSL Research University, CNRS, INSERM, UMR3347, U1021, Orsay, France.
Simon SauleInstitut Curie, PSL Research University, CNRS, INSERM, UMR3347, U1021, Orsay, France; Université Paris-Saclay Centre National de La Recherche Scientifique, UMR 3347, Unité 1021, Orsay, France.
Aurélie TeissandierInstitut Curie, PSL Research University, Sorbonne University, INSERM U934, CNRS UMR 3215, 75005 Paris, France.
Deborah Bourc'hisInstitut Curie, PSL Research University, Sorbonne University, INSERM U934, CNRS UMR 3215, 75005 Paris, France.
Elodie GirardINSERM U900, Mines ParisTech, 75248 Paris, France.
Jennifer WongDepartment of Diagnostic and Theranostic Molecular Pathology, Unit of Somatic Genetic, Hospital, Institut Curie, Paris, France.
Julien Masliah-PlanchonDepartment of Diagnostic and Theranostic Molecular Pathology, Unit of Somatic Genetic, Hospital, Institut Curie, Paris, France.
Erkan NarmanliTranslational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; INSERM U830, Research Center, Institut Curie, PSL Research University, 75005 Paris, France.
Yuanlong LiuDepartment of Computational Biology, University of Lausanne, Lausanne, Switzerland; Swiss Cancer Center Leman, Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Emma TorunInstitut Curie, PSL Research University, Sorbonne University, INSERM U934, CNRS UMR 3215, 75005 Paris, France.
Rebecca GoulancourtGenoSplice, Paris, France.
Manuel RodriguesDepartment of Medical Oncology, Institut Curie, PSL Research University, 75005 Paris, France; INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée par la Ligue Nationale Contre le Cancer, Department of Genetics, Institut Curie, PSL Research University, 75005 Paris, France.
Laure Villoing GaudéTranslational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France.
Cécile ReyesTranslational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France.
Matéo BazireTranslational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France.
Thomas ChenegrosTranslational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France.
Emilie HenryTranslational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France.
Audrey RapinatTranslational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Genomics Platform, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France.
Mylene BohecInstitut Curie Genomics of Excellence (ICGex) Platform, Institut Curie Research Center, PSL Research University, Paris, France.
Sylvain BaulandeInstitut Curie Genomics of Excellence (ICGex) Platform, Institut Curie Research Center, PSL Research University, Paris, France.
Radhia M'kacherCell Environment, DNA Damage R&D, 75020 Paris, France.
Eric JeandidierLaboratoire de Génétique, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, Mulhouse, France.
André NicolasPathex, Institut Curie, PSL Research University, Paris, France.
Giovanni CirielloDepartment of Computational Biology, University of Lausanne, Lausanne, Switzerland; Swiss Cancer Center Leman, Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Raphael MargueronInstitut Curie, PSL Research University, Sorbonne University, INSERM U934, CNRS UMR 3215, 75005 Paris, France.
Didier DecaudinTranslational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, 75248 Paris, France.
Nathalie CassouxDepartment of Medical Oncology, Institut Curie, PSL Research University, 75005 Paris, France; Department of Ocular Oncology, Faculty of Medicine, Institut Curie, Université de Paris Descartes, 75005 Paris, France.
Sophie Piperno-NeumannDepartment of Medical Oncology, Institut Curie, PSL Research University, 75005 Paris, France.
Marc-Henri SternINSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée par la Ligue Nationale Contre le Cancer, Department of Genetics, Institut Curie, PSL Research University, 75005 Paris, France.
Johan Harmen GibcusDepartment of Systems Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Job DekkerHoward Hughes Medical Institute, Department of Systems Biology, Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Edith HeardDirector's Unit, European Molecular Biology Laboratory, 69117 Heidelberg, Germany.
Sergio Roman-RomanTranslational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France. Electronic address: sergio.roman-roman@curie.fr.
Joshua J WaterfallTranslational Research Department, Research Center, Institut Curie, Paris Sciences et Lettres (PSL) Research University, 75005 Paris, France; INSERM U830, Research Center, Institut Curie, PSL Research University, 75005 Paris, France. Electronic address: joshua.waterfall@curie.fr.
Université Paris Sciences et Lettres · FRInserm · FRCentre National de la Recherche Scientifique · FRInstitut Curie · FRSIB Swiss Institute of Bioinformatics · CHEuropean Molecular Biology Laboratory · DEGroupe Hospitalier de la Région de Mulhouse et Sud Alsace · FRHoward Hughes Medical Institute · USUniversité Paris Cité · FRUniversity of Massachusetts Chan Medical School · US
Funding
Structural Annotation of the Human GenomeR01HG003143 · NHGRI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Job Dekker · 2003 to 2026
$15.4MComplex Trait Consortium 2004, 3rd Annual ConferenceR13HG003431 · NHGRI · JACKSON LABORATORY · PI BOGUE, MOLLY A · 2004 to 2004
$21kHoward Hughes Medical InstituteNHGRI NIH HHS R01 HG003143NHGRI NIH HHS R13 HG003431
Abstract
Uveal melanoma (UM) is a rare cancer resulting from the transformation of melanocytes in the uveal tract. Integrative analysis has identified four molecular and clinical subsets of UM. To improve our molecular understanding of UM, we performed extensive multi-omics characterization comparing two aggressive UM patient-derived xenograft models with normal choroidal melanocytes, including DNA optical mapping, specific histone modifications, and DNA topology analysis using Hi-C. Our gene expression and cytogenetic analyses suggest that genomic instability is a hallmark of UM. We also identified a recurrent deletion in the BAP1 promoter resulting in loss of expression and associated with high risk of metastases in UM patients. Hi-C revealed chromatin topology changes associated with the upregulation of PRAME, an independent prognostic biomarker in UM, and a potential therapeutic target. Our findings illustrate how multi-omics approaches can improve our understanding of tumorigenesis and reveal two distinct mechanisms of gene expression dysregulation in UM.
Indexed as
MelanomaMultiomicsAntigens, NeoplasmDNAHumansMelanocytesUveal MelanomaUveal NeoplasmsAntigens, NeoplasmDNAPRAME protein, humanBAP1CP: Cancergenome instabilitymulti-omicsPRAMEuveal melanoma
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.